Ascending Doses of Crofelemer Powder for Oral Solution in Pediatric Microvillus Inclusion Disease (MVID)

计划入组 6 人 · 首次发布于 2024 年 12 月 6 日

VictORION-INCLUSION: Evaluating Inclisiran for Cholesterol Managment in Heart Disease

计划入组 130 人 · 首次发布于 2024 年 2 月 8 日

Structural and Functional Changes in Neuronal Intranuclear Inclusion Disease(NIID)

计划入组 30 人 · 首次发布于 2019 年 8 月 14 日

liver disease program

siRNA therapeutics for ocular disease/dermatological disease (Phio Pharmaceuticals)

undisclosed drug (fibrotic liver disease/NASH), Engitix/Takeda

Rare Disease Research, LLC

CASTLEMAN DISEASE COLLABORATIVE NETWORK

United States

CURE RARE DISEASE, INC.

United States

Jaguar Health's Napo Therapeutics Advances Crofelemer for Rare Intestinal Diseases in Europe

Crofelemer Receives FDA Orphan Drug Designation for Cholera-Related Diarrhea

Jaguar Health Advances Crofelemer Trials for Rare Diarrheal Diseases